Effectiveness of Multistrain Versus Single-strain Probiotics Current Status and Recommendations for the Future

Journal of Clinical Gastroenterology

Volumn 52, Issue , 2018, Pages S35-S40

  Ouwehand, Arthur C ^a   Invernici, Marcos M ^b   Furlaneto, Flávia A C ^b   Messora, Michel R ^b  

^a DUPONT COMPANY   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Lactobacillus, Bifidobacterium, efficacy; probiotic

Indexed keywords

MULTISTRAIN PROBIOTIC; PROBIOTIC AGENT; SINGLE STRAIN PROBIOTIC; UNCLASSIFIED DRUG;

ANTAGONISTIC EFFECT; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BACTERIAL LOAD; GASTROINTESTINAL DISEASE; META ANALYSIS (TOPIC); MICROBIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BACTERIAL LOAD; GASTROINTESTINAL DISEASES; HUMANS; META-ANALYSIS AS TOPIC; PROBIOTICS; TREATMENT OUTCOME;

EID: 85055419663     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000001052     Document Type: Article

References (92)

1. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11:506-514.
2. Timmerman HM, Koning CJ, Mulder L, et al. Monostrain, multistrain and multispecies probiotics-a comparison of functionality and efficacy. Int J Food Microbiol. 2004;96: 219-233.
3. Zoppi G, Cinquetti M, Benini A, et al. Modulation of the intestinal ecosystem by probiotics and lactulose in children during treatment with ceftriaxone. Curr Ther Res Clin Exp. 2001; 62:418-435.
4. Ouwehand AC. A review of dose-responses of probiotics in human studies. Benef Microbes. 2016;8:1-10.
5. Applegate JA, Fischer Walker CL, Ambikapathi R, et al. Systematic review of probiotics or the treatment of communityacquired acute diarrhea in children. BMC Public Health. 2013;13 (suppl 3):S16.
6. Canani RB, Cirillo P, Terrin G, et al. Probiotics for treatment of acute diarrhoea in children: randomised clinical trial of five different preparations. BMJ. 2007;335:340.
7. Leyer GJ, Li S, Mubasher ME, et al. Probiotic effects on cold and influenza-like symptom incidence and duration in children. Pediatrics. 2009;124:e172-e179.
8. West NP, Horn PL, Pyne DB, et al. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr. 2014;33:581-587.
9. West NP, Horn PL, Barrett S, et al. Supplementation with a single and double strain probiotic on the innate immune system for respiratory illness. e-SPEN J. 2014;9:e178-e184.
10. West NP, Horn PL, Pyne DB, et al. Probiotic supplementation has little effect on peripheral blood regulatory T-cells. J Allergy Clin Immunol. 2016;138:1749-1752. e7.
11. Cox AJ, West NP, Horn PL, et al. Effects of probiotic supplementation over 5 months on routine haematology and clinical chemistry measures in healthy active adults. Eur J Clin Nutr. 2014;68:1255-1257.
12. Cabana MD, McKean M, Caughey AB, et al. Early probiotic supplementation for eczema and asthma prevention: a randomized controlled trial. Pediatrics. 2017;140.
13. Ou CY, Kuo HC, Wang L, et al. Prenatal and postnatal probiotics reduces maternal but not childhood allergic diseases: a randomized, double-blind, placebo-controlled trial. Clin Exp Allergy. 2012;42:1386-1396.
14. Simpson MR, Dotterud CK, Storro O, et al. Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial. BMC Dermatol. 2015;15:13.
15. Dotterud CK, Storro O, Johnsen R, et al. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br J Dermatol. 2010;163:616-623.
16. Kalliomäki M, Salminen S, Arvilommi H, et al. Probiotics in primary prevention of atopic disease: a randomised placebocontrolled trial. Lancet. 2001;357:1076-1079.
17. Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy. 2002;57:243-246.
18. Rose MA, Stieglitz F, Koksal A, et al. Efficacy of probiotic lactobacillus GG on allergic sensitization and asthma in infants at risk. Clin Exp Allergy. 2010;40:1398-1405.
19. Baldassarre ME, Laforgia N, Fanelli M, et al. Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr. 2010;156:397-401.
20. Hatakka K, Savilahti E, Pönkä A, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. Br Med J. 2001;322:1-5.
21. Laursen RP, Larnkjaer A, Ritz C, et al. Probiotics and child care absence due to infections: a randomized controlled trial. Pediatrics. 2017;140.
22. Smith TJ, Rigassio-Radler D, Denmark R, et al. Effect of Lactobacillus rhamnosus LGG(R) and Bifidobacterium animalis ssp. lactis BB-12(R) on health-related quality of life in college students affected by upper respiratory infections. Br J Nutr. 2013; 109:1999-2007.
23. Berni Canani R, Di Costanzo M, Bedogni G, et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3-year randomized controlled trial. J Allergy Clin Immunol. 2017;139:1906. e1904-1913. e1904.
24. Bruzzese E, Fedele MC, Bruzzese D, et al. Randomised clinical trial: a Lactobacillus GG and micronutrient-containing mixture is effective in reducing nosocomial infections in children, vs. placebo. Aliment Pharmacol Ther. 2016;44:568-575.
25. Hojsak I, Abdovic S, Szajewska H, et al. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics. 2010;125:e1171-e1177.
26. Jerzynska J, Stelmach W, Balcerak J, et al. Effect of Lactobacillus rhamnosus GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy. Allergy Asthma Proc. 2016;37:324-334.
27. West NP, Pyne DB, Cripps AW, et al. Gut balance, a synbiotic supplement, increases fecal Lactobacillus paracasei but has little effect on immunity in healthy physically active individuals. Gut Microbes. 2012;3:221-227.
28. Jäsberg H, Tervahartiala T, Sorsa T, et al. Probiotic intervention influences the salivary levels of Matrix Metalloproteinase (MMP)-9 and Tissue Inhibitor of metalloproteinases (TIMP)-1 in healthy adults. Arch Oral Biol. 2018;85: 58-63.
29. Korpela K, Salonen A, Virta LJ, et al. Lactobacillus rhamnosus GG intake modifies preschool children's intestinal microbiota, alleviates penicillin-associated changes, and reduces antibiotic use. PLoS One. 2016;11:e0154012.
30. Tapiovaara L, Kumpu M, Makivuokko H, et al. Human rhinovirus in experimental infection after peroral Lactobacillus rhamnosus GG consumption, a pilot study. Int Forum Allergy Rhinol. 2016;6:848-853.
31. Luoto R, Ruuskanen O, Waris M, et al. Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2014;133:405-413.
32. Hojsak I, Snovak N, Abdovic S, et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, doubleblind, placebo-controlled trial. Clin Nutr. 2010;29:312-316.
33. Lehtoranta L, Kalima K, He L, et al. Specific probiotics and virological findings in symptomatic conscripts attending military service in Finland. J Clin Virol. 2014;60:276-281.
34. Kumpu M, Kekkonen RA, Kautiainen H, et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebocontrolled trial. Eur J Clin Nutr. 2012;66:1020-1023.
35. Kwon JH, Bommarito KM, Reske KA, et al. Randomized controlled trial to determine the impact of probiotic administration on colonization with multidrug-resistant organisms in critically Ill patients. Infect Control Hosp Epidemiol. 2015;36: 1451-1454.
36. Doron S, Hibberd PL, Goldin B, et al. Effect of Lactobacillus rhamnosus GG administration on vancomycin-resistant enterococcus colonization in adults with comorbidities. Antimicrob Agents Chemother. 2015;59:4593-4599.
37. Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain Lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45: 872-877.
38. Padilla Ruiz M, Fernandez Aguiar ME, Arce Nunez M, et al. Lactobacillus rhamnosus GG supplementation to reduce sideeffects of anti-Helicobacter pylori treatment. Rev Gastroenterol Peru. 2013;33:121-130.
39. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of Lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48:431-436.
40. Hauser G, Salkic N, Vukelic K, et al. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 2015;94:e685.
41. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001;15:163-169.
42. Partty A, Lehtonen L, Kalliomaki M, et al. Probiotic Lactobacillus rhamnosus GG therapy and microbiological programming in infantile colic: a randomized, controlled trial. Pediatr Res. 2015;78:470-475.
43. Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol. 2011;31:63-69.
44. Van Niekerk E, Nel DG, Blaauw R, et al. Probiotics reduce necrotizing enterocolitis severity in HIV-exposed premature infants. J Trop Pediatr. 2015;61:155-164.
45. Dani C, Biadaioli R, Bertini G, et al. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate. 2002;82:103-108.
46. Rouge C, Piloquet H, Butel MJ, et al. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr. 2009;89:1828-1835.
47. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc. 2001;76:883-889.
48. Fox MJ, Ahuja KD, Robertson IK, et al. Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study. BMJ Open. 2015;5: e006474.
49. Wenus C, Goll R, Loken EB, et al. Prevention of antibioticassociated diarrhoea by a fermented probiotic milk drink. Eur J Clin Nutr. 2008;62:299-301.
50. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infecions: a randomised study. Pediatrics. 1999; 104:e64.
51. Mayes T, Gottschlich MM, James LE, et al. Clinical safety and efficacy of probiotic administration following burn injury. J Burn Care Res. 2015;36:92-99.
52. Lien TH, Bu LN, Wu JF, et al. Use of Lactobacillus casei rhamnosus to prevent cholangitis in biliary atresia after kasai operation. J Pediatr Gastroenterol Nutr. 2015;60:654-658.
53. Pedersen N, Andersen NN, Vegh Z, et al. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol. 2014;20:16215-16226.
54. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27:48-57.
55. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr. 2005;147:197-201.
56. Francavilla R, Miniello V, Magista AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126:e1445-e1452.
57. Aggarwal S, Upadhyay A, Shah D, et al. Lactobacillus GG for treatment of acute childhood diarrhoea: an open labelled, randomized controlled trial. Indian J Med Res. 2014;139: 379-385.
58. Nixon AF, Cunningham SJ, Cohen HW, et al. The effect of Lactobacillus GG on acute diarrheal illness in the pediatric emergency department. Pediatr Emerg Care. 2012;28: 1048-1051.
59. Ferrie S, Daley M. Lactobacillus GG as treatment for diarrhea during enteral feeding in critical illness: randomized controlled trial. JPEN J Parenter Enteral Nutr. 2011;35:43-49.
60. Sindhu KN, Sowmyanarayanan TV, Paul A, et al. Immune response and intestinal permeability in children with acute gastroenteritis treated with Lactobacillus rhamnosus GG: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2014;58:1107-1115.
61. Marttinen A, Haukioja A, Karjalainen S, et al. Short-term consumption of probiotic lactobacilli has no effect on acid production of supragingival plaque. Clin Oral Investig. 2012; 16:797-803.
62. Toiviainen A, Jalasvuori H, Lahti E, et al. Impact of orally administered lozenges with Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12 on the number of salivary mutans streptococci, amount of plaque, gingival inflammation and the oral microbiome in healthy adults. Clin Oral Investig. 2015;19:77-83.
63. Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther. 2014;39:1113-1125.
64. Bruzzese E, Callegari ML, Raia V, et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial. PLoS One. 2014;9:e87796.
65. Partty A, Luoto R, Kalliomaki M, et al. Effects of early prebiotic and probiotic supplementation on development of gut microbiota and fussing and crying in preterm infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;163:1272-1277; e1271-1272.
66. Davidson LE, Fiorino AM, Snydman DR, et al. Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebocontrolled trial. Eur J Clin Nutr. 2011;65:501-507.
67. Ilmonen J, Isolauri E, Poussa T, et al. Impact of dietary counselling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebo-controlled trial. Clin Nutr. 2011;30:156-164.
68. Vajro P, Mandato C, Licenziati MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr. 2011;52:740-743.
69. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182:1058-1064.
70. Barraud D, Blard C, Hein F, et al. Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med. 2010;36:1540-1547.
71. Laitinen K, Poussa T, Isolauri E. Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial. Br J Nutr. 2009;101: 1679-1687.
72. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy-a randomised, double-blind, placebo-controlled study. Br J Nutr. 2009;101: 1722-1726.
73. Hatakka K, Blomgren K, Pohjavuori S, et al. Treatment of acute otitis media with probiotics in otitis-prone children-a double-blind, placebo-controlled randomised study. Clin Nutr. 2007;26:314-321.
74. Zocco MA, dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1567-1574.
75. Bousvaros A, Guandalini S, Baldassano RN, et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005;11:833-839.
76. Kuisma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509-515.
77. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405-409.
78. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining of Crohn's disease. BMC Gastroenterol. 2004;4:1-4.
79. Näse L, Hatakka K, Savilahti E, et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35:412-420.
80. Ouwehand AC, Isolauri E, Kirjavainen PV, et al. The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett Appl Microbiol. 2000;30:10-13.
81. Ahmed M, Prasad J, Gill H, et al. Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. J Nutr Health Aging. 2007;11:26-31.
82. Cox MJ, Huang YJ, Fujimura KE, et al. Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome. PLoS One. 2010;5:e8745.
83. Kristensen NB, Bryrup T, Allin KH, et al. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Med. 2016;8:52.
84. Engelbrektson A, Korzenik JR, Pittler A, et al. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. JMedMicrobiol. 2009;58:663-670.
85. Kabbani TA, Pallav K, Dowd SE, et al. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017;8:17-32.
86. Forssten SD, Ouwehand AC. Simulating colonic survival of probiotics in single-strain products compared to multi-strain products. Microb Ecol Health Dis. 2017;28:1378061.
87. Morovic W, Roper JM, Smith AB, et al. Safety evaluation of HOWARU((R)) Restore (Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium animalis subsp. lactis Bl-04 and B. lactis Bi-07) for antibiotic resistance, genomic risk factors, and acute toxicity. Food Chem Toxicol. 2017;110:316-324.
88. Kumpu M, Swanljung E, Tynkkynen S, et al. Recovery of probiotic Lactobacillus rhamnosus GG in tonsil tissue after oral administration: randomised, placebo-controlled, double-blind clinical trial. Br J Nutr. 2013;109:2240-2246.
89. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35-37.
90. Ringel-Kulka T, Goldsmith JR, Carroll IM, et al. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain-a randomised clinical study. Aliment Pharmacol Ther. 2014;40: 200-207.
91. D'Souza B, Slack T, Wong SW, et al. Randomized controlled trial of probiotics after colonoscopy. ANZ J Surg. 2017;87: E65-E69.
92. Plaza-Diaz J, Robles-Sanchez C, Abadia-Molina F, et al. Adamdec1, Ednrb and Ptgs1/Cox1, inflammation genes upregulated in the intestinal mucosa of obese rats, are downregulated by three probiotic strains. Sci Rep. 2017;7:1939.